Clinical characteristics of the patients included in the study
| No. of patients | 536 |
| Median age (range), y | 34 (0-59) |
| Sex (male:female) | 311:225 |
| Diagnosis | |
| Acute lymphoblastic leukemia | 124 |
| Acute myelogenous leukemia | 163 |
| Chronic myeloid leukemia | 158 |
| Multiple myeloma | 11 |
| Non-Hodgkin lymphoma | 35 |
| Hodgkin disease | 2 |
| Myelodysplastic syndrome | 34 |
| Other | 9 |
| Disease stage (early:advanced) | 326:175 |
| Sex mismatch, n (%) | 132 (24.8) |
| Sensitized donor, n (%) | 96 (20.1) |
| Source of stem cells (PB:BM) | 270:266 |
| Conditioning regimens | |
| Cyclophosphamide + TBI | 206 |
| Busulfan + cyclophosphamide | 308 |
| Other | 20 |
| GVHD prophylaxis | |
| CSA | 29 |
| CSA + MTX | 485 |
| CSA + MTX + corticosteroids | 2 |
| CSA + corticosteroids | 20 |
| No. of patients | 536 |
| Median age (range), y | 34 (0-59) |
| Sex (male:female) | 311:225 |
| Diagnosis | |
| Acute lymphoblastic leukemia | 124 |
| Acute myelogenous leukemia | 163 |
| Chronic myeloid leukemia | 158 |
| Multiple myeloma | 11 |
| Non-Hodgkin lymphoma | 35 |
| Hodgkin disease | 2 |
| Myelodysplastic syndrome | 34 |
| Other | 9 |
| Disease stage (early:advanced) | 326:175 |
| Sex mismatch, n (%) | 132 (24.8) |
| Sensitized donor, n (%) | 96 (20.1) |
| Source of stem cells (PB:BM) | 270:266 |
| Conditioning regimens | |
| Cyclophosphamide + TBI | 206 |
| Busulfan + cyclophosphamide | 308 |
| Other | 20 |
| GVHD prophylaxis | |
| CSA | 29 |
| CSA + MTX | 485 |
| CSA + MTX + corticosteroids | 2 |
| CSA + corticosteroids | 20 |
Advanced disease was considered for patients with acute leukemia beyond first complete remission, chronic myeloid leukemia beyond first chronic phase, and progressive disease for patients with myelodysplastic syndrome, multiple myeloma, or lymphoma. Sensitized donor corresponds to donors with previous pregnancies or transfusions. PB indicates peripheral blood; BM, bone marrow; TBI, total body irradiation; CSA, cyclosporin A; and MTX, methotrexate.